The Norwegian experience with penicillin G plus an aminoglycoside as initial empiric therapy in febrile neutropenia; a review

References

• Statens Helsetilsyn. Bruk av antibiotika i sykehus. Smittevernloven. Håndbok (in Norwegian). Oslo: Statens Helsetilsyn; 2001. IK-2737.
   Google Scholar
• NORM/NORM-VET 2010. Usage of antimicrobial agents and occurrence of antimicrobial resistance in Norway. Tromsø/Oslo: NORM, 2010. Available from: www.antibiotikaresistens.no
   Google Scholar
• Nasjonal strategi for forebygging av infeksjoner i helsetjenesten og antibiotikaresistens (2008–2012). Helse-og omsorgsdepartementet (in Norwegian); [email protected]
   Google Scholar
• Frøland SS, Myrvang B, Evensen S, Lingaas E. Monoterapi med ceftazidim hos pasienter med akutt leukemi og granulocytopeni. Erfaringer fra Rikshospitalet (in Norwegian). Norsk Ceftazidim Symposium. Oslo: Glaxo; 1990. p.45–50.
   Google Scholar
• Hammerstrøm J, Jacobsen T. Bakteriemi ved granulocytopeni-mikrobiologi og empirisk antibiotikabehandling (in Norwegian). Tidsskr Nor Legeforen 1998;118:4370–5.
   PubMedGoogle Scholar
• Tangen JM, Berentsen S, Dahl IM, Ly B, Myrvang B. Empirisk antibiotikabehandling hos pasienter med akutt myelogen leukemi (in Norwegian). Tidsskr Nor Legeforen 1999;119:35–8.
   PubMedGoogle Scholar
• Hammerstrøm J, Roym AL, Gran FW. Bakteriemi ved maligne blodsykdommer (in Norwegian). Tidsskr Nor Legeforen 2008;128:1655–9.
   PubMedGoogle Scholar
• Sigurdardottir K, Digranes A, Harthug S, Nesthus I, Tangen JM, Meyer P, . A multi-centre prospective study of febrile neutropenia in Norway: Microbiological findings and antimicrobial susceptibility. Scand J Infect Dis 2005;37:455–64.
   PubMed Web of Science ®Google Scholar
• Torfoss D, Høiby EA, Tangen JM, Holte H, Bø K, Meyer P, . Tobramycin once versus three times daily, given with penicillin G, to febrile neutropenic cancer patients in Norway: A prospective, randomized, multicentre trial. J Antimicrob Chemother 2007;59:711–7.
   PubMed Web of Science ®Google Scholar
• Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, . The Multinational Association for Supportive Care in Cancer Risk Index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18:3038–51.
   PubMed Web of Science ®Google Scholar
• Stabell N, Nordal E, Stensvold E, Wiger Gammelsrud K, Lund B, Taxt A, . Febrile neutropenia in children with cancer: A retrospective Norwegian multicentre study of clinical and microbiological outcome. Scand J Infect Dis 2008;40:301–7.
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, . Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011;52:e56–93.
   PubMed Web of Science ®Google Scholar
• Paul M, Yahav D, Fraser A, Leibovici L. Empirical antibiotic monotherapy for febrile neutropenia: Systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2006;57:176–89.
   PubMed Web of Science ®Google Scholar
• Paul M, Soares-Weiser K, Grozinsky S, Leibovici L. Beta-lactam versus beta-lactam–aminoglycoside combination therapy in cancer patients with neutropenia. Cochrane Database Syst Rev 2002;CD003038.
   PubMedGoogle Scholar
• Klastersky J. Empirical antibiotic therapy in neutropenic cancer patients. Eur J Cancer 1993;29A:S6–10.
   PubMedGoogle Scholar
• Sonne M, Jawetz E. Combined action of carbencillin and gentamicin on Pseudomonas aeruginosa in vitro. Applied Microbiol 1969;17:893–6.
   PubMedGoogle Scholar
• Song W, Woo HJ, Kim JS, Lee KM. In vitro activity of β-lactams in combination with other antimicrobial agents against resistant strains of Pseudomonas aeruginosa. Int J Antimicrob Agents 2003;21:8–12.
   PubMed Web of Science ®Google Scholar
• Bodey GP, Middleman E, Umsawadi T, Rodriguez V. Infections in cancer patients. Results with gentamicin sulphate therapy. Cancer 1972;29:1697–701.
   PubMed Web of Science ®Google Scholar
• Bodey GP, Rodriguez V. Advances in the management of Pseudomonas aeruginosa infections in cancer patients. Eur J Cancer 1973;9:435–41.
   PubMed Web of Science ®Google Scholar
• Schimpff S, Satterlee W, Young VM, Serpick A. Empiric therapy with carbencillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971;284: 1061–5.
   PubMed Web of Science ®Google Scholar
• Craig WA. Pharmacokinetic/pharmacodynamic parameters: Rationale for antimicrobial dosing of mice and men. Clin Infect Dis 1998;26:1–12.
   PubMed Web of Science ®Google Scholar
• Keating MJ, Bodey GP, Valdivieso M, Rodriguez V. A randomized comparative trial of three aminoglycosides – comparison of continuous infusions of gentamicin, amikacin and sisomicin combined with carbencillin in the treatment of infections in neutropenic patients with malignancies. Medicine 1979;58:159–70.
   PubMed Web of Science ®Google Scholar
• de Man P, Verhoeven BAN, Verbrugh HA, Vos MC, van den Anker JN. An antibiotic policy to prevent emergence of resistant bacilli. Lancet 2000;355:973–8.
   PubMed Web of Science ®Google Scholar
• Bliziotis IA, Samonis G, Vardakas KZ, Chrysanthopoulou S, Falagas ME. Effect of aminoglycoside and β-lactam combination therapy versus β-lactam monotherapy on the emergence of antimicrobial resistance: A metaanalysis of randomized, controlled trials. Clin Infect Dis 2005;41: 149–58.
   PubMed Web of Science ®Google Scholar
• Vander Stichele RH, Elseviers MM, Ferech M, Blot S, Goossens H. Hospital consumption of antibiotics in 15 European countries: Results of the ESAC retrospective data collection (1997–2002). J Antimicrob Chemother 2006;58: 159–67.
   PubMed Web of Science ®Google Scholar
• McGowan JE Jr. Antimicrobial resistance in hospital organisms and its relation to antibiotic use. Rev Infect Dis 1983;5:1033–48.
   PubMedGoogle Scholar
• Austin DJ, Kristinsson KG, Anderson RM. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proc Natl Acad Sci USA 1999;96:1152–6.
   PubMed Web of Science ®Google Scholar
• Freundlich M, Thomsen RW, Pedersen L, West H, Schønheyder C. Aminoglycoside treatment and mortality after bacteraemia in patients given appropriate empirical therapy: A Danish hospital-based cohort study. J Antimicrob Chemother 2007;60:1115–23.
   PubMed Web of Science ®Google Scholar
• Leibovici L, Paul M. Aminoglycoside/β-lactam combinations in clinical practice. J Antimicrob Chemother 2007;60:911–2.
   PubMedGoogle Scholar